Greg B. Petersen occupies the position of President at BrookView Capital LLC, President at Brookview Capital Advisors and Chief Financial Officer of Activant Solutions Holdings, Inc. Mr. Petersen is also on the board of PROS Holdings, Inc., Mohawk Group, Inc., Plus Therapeutics, Inc. and Aterian, Inc.
In the past he was President for Texas Capital Advisors LLC, Chief Financial Officer at Q2 Holdings, Inc. and Chief Financial Officer & Executive VP-Operations at Q2 Software, Inc. (a subsidiary of Q2 Holdings, Inc.), Principal at Trilogy Enterprises, Inc. and Vice President-Finance of Versata Software, Inc. (a subsidiary of Trilogy Enterprises, Inc.), Chief Financial Officer & Executive Vice President at Activant Solutions, Inc., Chief Financial Officer for Lombardi Software, Inc., Managing Director-Corporate Development at American Airlines, Inc. and SVP-Planning & Business Development at RailTex, Inc.
He received an undergraduate degree from Boston College and an MBA from The Fuqua School of Business.
What is Greg Petersen's net worth?
The estimated net worth of Greg Petersen is at least $41,323.86 as of September 11th, 2023. Mr. Petersen owns 24,166 shares of Plus Therapeutics stock worth more than $41,324 as of April 18th. This net worth approximation does not reflect any other assets that Mr. Petersen may own. Learn More about Greg Petersen's net worth.
How do I contact Greg Petersen?
Has Greg Petersen been buying or selling shares of Plus Therapeutics?
Greg Petersen has not been actively trading shares of Plus Therapeutics during the last ninety days. Most recently, on Monday, September 11th, Greg Petersen bought 20,000 shares of Plus Therapeutics stock. The stock was acquired at an average cost of $1.70 per share, with a total value of $34,000.00. Following the completion of the transaction, the director now directly owns 24,166 shares of the company's stock, valued at $41,082.20. Learn More on Greg Petersen's trading history.
Who are Plus Therapeutics' active insiders?
Are insiders buying or selling shares of Plus Therapeutics?
In the last year, Plus Therapeutics insiders bought shares 9 times. They purchased a total of 43,888 shares worth more than $77,812.49. In the last year, insiders at the sold shares 1 times. They sold a total of 2,068 shares worth more than $4,053.28. The most recent insider tranaction occured on November, 20th when CEO Marc H Hedrick sold 2,068 shares worth more than $4,053.28. Insiders at Plus Therapeutics own 2.3% of the company.
Learn More about insider trades at Plus Therapeutics. Information on this page was last updated on 11/20/2023.
